Adaptimmune Therapeutics Stock Forecast

ADAP's stock price has decreased by -70.54% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 6 professional analysts, the 12-month price target for Adaptimmune Therapeutics stock ranges from a low of $0.46 to a high of $3.00. The average analyst price target of $1.35 forecasts a 451.02% increase in the stock price over the next year.

Price Target: $1.35 (+451.02%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$0.46	$1.35	$1.40	$3.00
Change	+87.76%	+451.02%	+471.43%	+1124.5%

Analyst Ratings

The average analyst rating for Adaptimmune Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25	Apr '25	May '25	Jun '25
Strong Buy	2	2	2	2	2	2
Buy	2	2	2	2	2	1
Hold	0	0	1	1	1	2
Sell	0	0	0	0	1	1
Strong Sell	0	0	0	0	0	0
Total	4	4	5	5	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Graig Suvannavejh Mizuho	Mizuho	Buy → Hold Downgrades $1.5 → $0.5	Buy → Hold	Downgrades	$1.5 → $0.5	+104.08%	Jun 26, 2025
Peter Lawson Barclays	Barclays	Sell Maintains $1 → $0.46	Sell	Maintains	$1 → $0.46	+87.76%	May 14, 2025
Yanan Zhu Wells Fargo	Wells Fargo	Hold Maintains $1.5 → $1	Hold	Maintains	$1.5 → $1	+308.16%	May 14, 2025
Arthur He HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $3.5 → $3	Strong Buy	Maintains	$3.5 → $3	+1,124.49%	Apr 1, 2025
Michael Schmidt Guggenheim	Guggenheim	Strong Buy Maintains $3 → $1.75	Strong Buy	Maintains	$3 → $1.75	+614.29%	Mar 26, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

50.98M

from 178.03M

-71.37%

from 178.03M

Revenue Next Year

69.07M

from 50.98M

35.48%

from 50.98M

EPS This Year

-0.47

from -0.30

EPS Next Year

-0.25

from -0.47

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	3.96M	6.15M	27.15M	60.28M	178.03M	50.98M	69.07M	125.09M
Revenue Growth	252.76%	55.36%	341.50%	122.05%	195.34%	-71.37%	35.48%	81.11%
EPS	-0.91	-1.02	-1.03	-0.57	-0.30	-0.47	-0.25	-0.28
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	7	8	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	66.2M	89.3M	159.7M
Avg	51.0M	69.1M	125.1M
Low	37.4M	36.0M	54.7M

Revenue Growth

Revenue Growth	2025	2026	2027
High	-62.8%	75.1%	131.2%
Avg	-71.4%	35.5%	81.1%
Low	-79.0%	-29.4%	-20.8%

EPS Forecast

EPS	2025	2026	2027
High	-0.42	-0.05	-0.16
Avg	-0.47	-0.25	-0.28
Low	-0.49	-0.48	-0.38

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.